Greenland Mines Secures Canadian Patent for Klotho Gene Therapy
Greenland Mines (GRML) secures Canadian patent for Klotho gene therapies targeting Alzheimer's, ALS, and other neurodegenerative diseases. Learn about KLTO-101 and KLTO-202.
This patent strengthens Greenland Mines' position in the growing field of gene therapies for neurodegenerative diseases, potentially accelerating development of treatments for conditions like Alzheimer's and ALS. For investors, it signals expanded IP protection and a clearer path to clinical milestones. For patients, it offers hope for new therapies targeting memory and cognition.